CL2021000329A1 - Compuestos útiles en terapia del vih - Google Patents

Compuestos útiles en terapia del vih

Info

Publication number
CL2021000329A1
CL2021000329A1 CL2021000329A CL2021000329A CL2021000329A1 CL 2021000329 A1 CL2021000329 A1 CL 2021000329A1 CL 2021000329 A CL2021000329 A CL 2021000329A CL 2021000329 A CL2021000329 A CL 2021000329A CL 2021000329 A1 CL2021000329 A1 CL 2021000329A1
Authority
CL
Chile
Prior art keywords
useful compounds
hiv therapy
compounds
hiv
therapy
Prior art date
Application number
CL2021000329A
Other languages
English (en)
Inventor
John Franklin Miller
David Temelkoff
Emile Johann Velthuisen
La Rosa Martha Alicia De
Lita Suwandi
B Narasimhulu Naidu
Original Assignee
Viiv Healthcare Co
Glaxosmithkline Ip No 2 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viiv Healthcare Co, Glaxosmithkline Ip No 2 Ltd filed Critical Viiv Healthcare Co
Publication of CL2021000329A1 publication Critical patent/CL2021000329A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/26Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32Nitrogen atom
    • C07D473/34Nitrogen atom attached in position 6, e.g. adenine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

La invención se refiere a compuestos de las fórmulas (I), (Ia), (II) y (IIa), sales de los mismos, composiciones farmacéuticas de los mismos, así como procedimientos para tratar o prevenir el VIH en sujetos.
CL2021000329A 2018-08-09 2021-02-08 Compuestos útiles en terapia del vih CL2021000329A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862716494P 2018-08-09 2018-08-09

Publications (1)

Publication Number Publication Date
CL2021000329A1 true CL2021000329A1 (es) 2021-09-03

Family

ID=68072882

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021000329A CL2021000329A1 (es) 2018-08-09 2021-02-08 Compuestos útiles en terapia del vih

Country Status (15)

Country Link
US (1) US20220117993A1 (es)
EP (1) EP3833437A1 (es)
JP (1) JP2021534112A (es)
KR (1) KR20210044806A (es)
CN (1) CN112789085A (es)
AR (1) AR115936A1 (es)
AU (1) AU2019317810A1 (es)
BR (1) BR112021002169A2 (es)
CA (1) CA3108635A1 (es)
CL (1) CL2021000329A1 (es)
IL (1) IL280660A (es)
MA (1) MA53280A (es)
MX (1) MX2021001612A (es)
TW (1) TW202023650A (es)
WO (1) WO2020031131A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113631563B (zh) 2019-01-25 2025-07-18 布朗大学 用于治疗、预防或逆转年龄相关炎症和疾病的组合物和方法
JP2022525013A (ja) 2019-03-06 2022-05-11 グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッド Hiv療法において有用な化合物
MX2022000563A (es) 2019-07-27 2022-06-17 Brii Biosciences Inc Derivado de adenosina y composición farmacéutica que lo comprende.
JP2022543319A (ja) * 2019-08-08 2022-10-11 グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッド Hiv治療に有用な化合物
KR20220156884A (ko) * 2020-03-20 2022-11-28 길리애드 사이언시즈, 인코포레이티드 4'-c-치환된-2-할로-2'-데옥시아데노신 뉴클레오시드의 프로드러그 및 이의 제조 및 사용 방법
KR20230132476A (ko) * 2021-01-25 2023-09-15 브리 바이오사이언시스, 인크. 아데노신 유도체 및 이를 포함하는 약제학적 조성물
EP4281083A4 (en) 2021-01-25 2025-01-01 Brii Biosciences, Inc. COMBINATION THERAPY FOR HIV WITH ADENOSINE DERIVATIVE AND CAPSID INHIBITORS

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB427857A (en) 1934-08-02 1935-05-01 Newsum Sons & Company Ltd H A new or improved system of construction for skeleton structures, particularly vehicle body frames and door frames
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
IL157940A0 (en) 2001-03-19 2004-03-28 Ono Pharmaceutical Co Drugs containing triazaspiro [5.5] undecane derivatives as the active ingredient
CA2502109C (en) * 2004-03-24 2010-02-23 Yamasa Corporation 4'-c-substituted-2-haloadenosine derivative
BRPI0811633A2 (pt) * 2007-05-14 2017-06-06 Univ Emory compostos de fórmulas (i) e (ii), método de tratamento de hospedeiro infectado por hiv-1, hiv-2, hbv ou hcv, método de prevenção de infecção por hiv-1, hiv-2, hbv ou hcv, método para reduzir atividade biológica de infecção por hiv-1, hiv-2, hbv ou hcv e composição farmacêutica
WO2015143712A1 (en) * 2014-03-28 2015-10-01 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors
KR102163611B1 (ko) * 2015-08-10 2020-10-08 머크 샤프 앤드 돔 코포레이션 항바이러스 베타-아미노산 에스테르 포스포디아미드 화합물
US20190185508A1 (en) * 2017-12-15 2019-06-20 Merck Sharp & Dohme Corp. Deuterated nucleoside reverse transcriptase inhibitors

Also Published As

Publication number Publication date
CN112789085A (zh) 2021-05-11
JP2021534112A (ja) 2021-12-09
AU2019317810A1 (en) 2021-02-25
KR20210044806A (ko) 2021-04-23
TW202023650A (zh) 2020-07-01
IL280660A (en) 2021-03-25
MA53280A (fr) 2021-11-17
EP3833437A1 (en) 2021-06-16
US20220117993A1 (en) 2022-04-21
BR112021002169A2 (pt) 2021-05-04
CA3108635A1 (en) 2020-02-13
AR115936A1 (es) 2021-03-17
MX2021001612A (es) 2021-05-13
WO2020031131A1 (en) 2020-02-13

Similar Documents

Publication Publication Date Title
CL2021000329A1 (es) Compuestos útiles en terapia del vih
UY37710A (es) Inhibidores de la replicación del virus de la inmunodeficiencia humana
MX2021004593A (es) Inhibidores de la replicacion del virus de la inmunodeficiencia humana.
ECSP20020410A (es) Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos
CO2021012579A2 (es) Compuestos útiles en la terapia del vih
CO2020007218A2 (es) Nuevas piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1
UY36648A (es) Inhibidores de la replicación del virus de inmunodeficiencia humana
CL2021001388A1 (es) Compuestos útiles en la terapia para el vih
UY36649A (es) Inhibidores de la replicación del virus de la inmunodeficiencia humana
MX2024004921A (es) Derivados de piperidinilindol, metodos de preparacion y usos medicinales de estos.
CR20190318A (es) Compuestos heterocíclicos como inmunomoduladores
PE20191474A1 (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cancer
CO2018004857A2 (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer
SV2018005750A (es) Derivados de compuestos de indol sustituidos como inhibidores de la replicacion virica del dengue
UY36212A (es) Moduladores de receptores tipo toll para el tratamiento del vih
MX2015011478A (es) Compuestos de amida para el tratamiento de vih.
ECSP18073293A (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
CL2019002240A1 (es) Dendrímeros terapéuticos.
UY36145A (es) Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer
MX2020012058A (es) Compuestos de triazolopirimidina y su uso en el tratamiento del cancer.
MX2017006536A (es) Derivados de piridincarboxamida, su metodo de preparacion y sus usos farmaceuticos.
CR20180091A (es) 5-(n-bencil-tetrahidroisoquinolin-6-il)-piridin-3-il acético como inhibidores de la replicación del vih
NI201600091A (es) UREAS ASIMÉTRICAS p-SUSTITUIDAS Y USOS MÉDICOS DE LAS MISMAS
CR20170157A (es) Derivados de nucleósidos sustituidos con 4´-vinilo como inhibidores de la replicación del arn del virus respiratorio sincitial
UY37729A (es) NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7